Uterine myoma after cessation of gonadotropin-releasing hormone agonist: Ultrasound and histopathologic findings

Chinese Medical Journal (Taipei)

Volumn 61, Issue 11, 1998, Pages 625-629

  Wang, Peng Hui ^a   Yang, An Hang ^a   Yuan, Chiou Chung ^a   Lee, Wen Ling ^a   Chao, Hsiang Tai ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Flow velocity waveform; Gonadotropin releasing hormone agonist therapy; Morphometry; Ultrastructure; Uterine myoma

Indexed keywords

ESTRADIOL; GONADORELIN AGONIST; GOSERELIN;

ARTICLE; CELL SIZE; CLINICAL ARTICLE; COLOR ULTRASOUND FLOWMETRY; DRUG WITHDRAWAL; ECHOGRAPHY; ESTRADIOL BLOOD LEVEL; FEMALE; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; MUSCLE FIBRIL; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR RECURRENCE; TUMOR VOLUME; UTERUS BLOOD FLOW; UTERUS MYOMA; UTERUS WEIGHT;

ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; GOSERELIN; HUMANS; LEIOMYOMA; MIDDLE AGED; PROSPECTIVE STUDIES; UTERINE NEOPLASMS; UTERUS;

EID: 0032433665     PISSN: 05781337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Buttram VC, Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 1981;36: 433-45.
2. Filicori M, Hall DA, Loughlin JS. A conservative approach to the management of uterine leiomyoma: pituitary desen-sitization by a luteinizing hormone-releasing analog. Am J Obstet Gynecol 1983;147:726-7.
3. Maheux R, Guilloteau C, Lemay A. Luteinizing hormone-releasing hormone agonist and uterine leiomyoma: a pilot study. Am J Obstet Gynecol 1985;152:1034-8.
4. Coddington CC, Collins RL, Shawker TH. Long-acting gonadotropin hormone-releasing hormone analog used to treat uteri. Fertil Steril 1986;45:624-9.
5. West CP, Lumsden MA, Lawson S. Shrinkage of uterine myomas during therapy with goserelin [Zoladex]: a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot. Fertil Steril 1987;48:45-51.
6. Crow J, Gardner RL, McSweeney G. Morphological changes in uterine leiomyomas treated by GnRH agonist goserelin. Int J Gynecol Pathol 1995;14:235-42.
7. Lumsden MA, West CP, Thomas E, Coutts J, Hillier H, Thomas N, Baird DT. Treatment with the gonadotrophin releasing hormone-agonist before hysterectomy for uterine fibroid. Br J Obstet Gynaecol 1994;101:438-42.
8. Shaw RW. Mechanism of LHRH analogue action in uterine myomas. Hormone Res 1989;32:150-3.
9. Amso N, McSweeney G, Burford G. A comparison of the effects of two isometric Gn-RH analogues on DMBA tumors in rats (Abstract). Br J Pharmacol 1982;75:53.
10. Matta WH, Stabile I, Shaw RW, Campbell S. Doppler assessment of uterine blood flow changes in patients with fibroids receiving the gonadotropin-releasing hormone agonist Buserelin. Fertil Steril 1988;49:1083-5.
11. Folkman J, Watson K, Ingber G, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58-61.
12. Crvenkovic G, Smrt C, Platt LD, Karlan BY. Strategies for ovarian cancer screening. In: Copel JA, Reed KL, eds. Doppler Ultrasound in Obstetrics and Gynecology. New York: Raven Press, 1995:55-60.
13. Demopoulos RI, Jones KY, Mittal KR, Vamvakas EC. Histology of leiomyoma in patients treated with leuprolide acetate. Int J Gynecol Pathol 1997;16:131-7.